Associated Papers
Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity.
Zhao M et al.
Cancer Biology & Therapy, 2019
Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.
Havelange V et al.
Journal of Blood Medicine, 2013
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Elling C et al.
Blood, 2011
Select a paper to view details